At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HEPA Hepion Pharmaceuticals, Inc.
Market Closed 05-17 16:00:00 EDT
1.30
+0.06
+4.84%
盘后1.20
-0.10-7.69%
19:41 EDT
High1.35
Low1.20
Vol28.05K
Open1.20
D1 Closing1.24
Amplitude12.50%
Mkt Cap7.11M
Tradable Cap6.49M
Total Shares5.47M
T/O35.91K
T/O Rate0.56%
Tradable Shares4.99M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.